Risk Stratification for Diffuse Large B‐Cell Lymphoma by Integrating Interim <sup>18</sup> F‐FDG PET‐CT Analysis and the NCCN‐IPI: A Multicenter Retrospective Study
Our study aimed to assess the prognostic significance of the interim National Comprehensive Cancer Network International Prognostic Index and PET-CT-related parameters for predicting patient outcomes and achieving precise risk stratification for diffuse large B-cell lymphoma (DLBCL) patients. We retrospectively analyzed the clinicopathological and PET-CT data of 498 patients diagnosed with DLBCL across three medical centers in China. 418 patients were eligible for subsequent analysis after excluding those with incomplete data and 70% of which were randomly selected as the discovery cohort, whereas the remaining 30% constituted the validation cohort. The impact of candidate factors on survival was assessed via univariate and multivariate Cox proportional hazards models. The area under the curve AUC and C-index were calculated to assess the predictive performance of models. Univariate and multivariate Cox regression analyses identified changes in total lesion glycolysis (ΔTLG), iNCCN-IPI, interim abdominal residual disease (iARD) status, and changes in the maximum standardized uptake value (ΔSUVmax) as independent prognostic factors. Leveraging the outcomes of the multivariate analysis, we constructed the iPET-NCCN-IPI prognostic model and categorized DLBCL patients into two separate prognostic risk groups based on their computed Risk Scores (RS = 0.90×iNCCN-IPI + 1.41×ΔTLG + 0.79×ΔSUVmax + 0.83×iARD). The predictive performance of the model was validated by calculating the area under the receiver operating characteristic curve and the C-index. Notably, compared with other models, the iPET-NCCN-IPI demonstrated superior prognostic capability. In conclusion, our study indicates that the iPET-NCCN-IPI stratifies DLBCL patients into two distinct prognostic risk groups and surpasses other models in prognostic predictive ability.
Authors
- Wenchen Gong (ORCID: https://orcid.org/0000-0002-7637-3538)
- Lihua Qiu (ORCID: https://orcid.org/0000-0003-4637-1811)
- Meifu Lin
- Jiesong Wang (ORCID: https://orcid.org/0000-0001-6846-0079)
- Huilai Zhang (ORCID: https://orcid.org/0000-0002-8558-3131)
- Jin He (ORCID: https://orcid.org/0000-0001-8283-7952)
- Qinghu Lyu
- Xia Liu (ORCID: https://orcid.org/0000-0002-3110-9602)
- Bin Meng (ORCID: https://orcid.org/0000-0003-4214-7011)
- Shiyong Zhou
- Zhengzi Qian
- Bei Yu
- Lei Zhu (ORCID: https://orcid.org/0000-0003-0213-3619)
- Zheng Song
- Yong Sun (ORCID: https://orcid.org/0009-0008-0281-5875)
- Lanfang Li (ORCID: https://orcid.org/0000-0003-3030-1739)
- Xiaofei Ye
- Shudan Zhai
- Xing Wan
- Xianhuo Wang
Institutions
- Fujian Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Fujian Provincial Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- Hematological Oncology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1002/hon.70118
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China